Kidney Failure Risk Calculator

Understanding Kidney Failure and KFRE

Kidney failure represents the terminal stage of chronic kidney disease, when glomerular filtration rate (eGFR) falls below 15 mL/min/1.73m² and the kidneys can no longer maintain electrolyte balance, fluid homeostasis, or waste elimination. This decline may occur gradually over years (chronic kidney disease) or acutely over days to weeks (acute kidney injury).

The Kidney Failure Risk Equation was developed from the Chronic Kidney Disease Epidemiology Collaboration and prospective cohort data to predict 2-year and 5-year progression to kidney replacement therapy (dialysis or transplant). Unlike static staging systems, KFRE incorporates dynamic biomarkers that reflect current renal physiology and systemic health, making it more precise for individual risk stratification.

Patients often experience:

• Progressive fatigue and cognitive fog from uremia
• Hyperphosphatemia-driven bone and vascular disease
• Hypertension and left ventricular hypertrophy
• Metabolic acidosis and mineral imbalances
• Gastrointestinal symptoms and reduced appetite

The Kidney Failure Risk Equation

The KFRE combines demographic and laboratory variables into a logistic regression model. Each input variable contributes points based on its value, and the cumulative score maps to a 5-year failure probability. The calculator performs two steps: first, it converts each biomarker into a component score; second, it sums all components and applies the logistic transformation to yield probability.

• Age — Patient age in years; older age increases risk weighting
• Sex — Biological sex; males typically receive higher risk scores
• eGFR — Estimated glomerular filtration rate in mL/min/1.73m²; lower values indicate worse renal function
• Albumin-to-Creatinine Ratio (ACR) — Urinary albumin excretion relative to creatinine; elevated ACR suggests glomerular damage
• Serum Albumin — Plasma albumin concentration in g/dL; low albumin may reflect malnutrition or nephrotic range proteinuria
• Serum Bicarbonate (HCO₃⁻) — Acid–base status marker in mEq/L; low bicarbonate indicates metabolic acidosis
• Serum Calcium — Total serum calcium in mg/dL; abnormalities reflect mineral metabolism dysfunction
• Serum Phosphorus — Serum phosphate in mg/dL; hyperphosphatemia predicts faster CKD progression

Key Considerations When Using KFRE

The following points help you interpret results accurately and avoid overconfidence in predictions.

1. Risk scores are population averages, not individual certainties — A 50% risk score means half of similar patients will reach kidney failure within five years—not that your individual timeline is predictable. Comorbidities (diabetes, hypertension, cardiovascular disease) and medication adherence significantly alter personal outcomes.
2. Validate with repeat testing and clinical context — Single-point laboratory measurements can fluctuate due to acute illness, dehydration, or transient infection. Request stable, consecutive eGFR and ACR values over 3 months before making major therapeutic changes.
3. KFRE performs best in CKD stage 3–4 — The equation was calibrated in cohorts with eGFR 20–60 mL/min/1.73m². Performance degrades below eGFR 20 or in dialysis-dependent patients. Always consult your nephrologist for individualized care.
4. Mineral abnormalities signal urgency but are correctable — Elevated phosphorus and low bicarbonate predict faster decline, but they respond to dietary modification, binders, and alkali supplementation. Managing these actively can slow progression independent of eGFR loss.

Clinical Applications and Next Steps

Nephrologists use KFRE scores to guide intensity of monitoring, medication initiation, and patient education. Patients with scores above 50% may benefit from earlier discussions about renal replacement modalities (in-center dialysis, home haemodialysis, peritoneal dialysis, or preemptive transplantation) and vascular access planning.

Evidence-based interventions that slow progression include:

• Antihypertensive therapy: ACE inhibitors or ARBs target proteinuria and glomerular pressure
• SGLT2 inhibitors: Emerging evidence supports cardio-renal protection across CKD stages
• Dietary counselling: Sodium and phosphorus restriction reduce mineral burden
• Anaemia management: Erythropoiesis-stimulating agents and iron repletion improve fatigue and cardiac function
• Bone health optimization: Active vitamin D analogues and phosphate binders preserve mineral integrity

Integrated nephrology care, dietetic input, and patient self-management—supported by longitudinal risk tracking—offer the best outcomes for slowing progression and preserving quality of life.